ConductScience.org, home
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
API referenceFor AI assistants

Trial · NCT03104400

Participant flow60

How many started, completed or left each group, period by period.

1 to 20 of 60

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Period 1 (Week 1 - 56)STARTEDPlacebo / Upadacitinib 15 mg211
Period 1 (Week 1 - 56)STARTEDPlacebo / Upadacitinib 30 mg212
Period 1 (Week 1 - 56)STARTEDAdalimumab 40 mg429
Period 1 (Week 1 - 56)STARTEDUpadacitinib 15 mg430
Period 1 (Week 1 - 56)STARTEDUpadacitinib 30 mg423
Period 1 (Week 1 - 56)STARTEDPlacebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)0
Period 1 (Week 1 - 56)STARTEDPlacebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260)0
Period 1 (Week 1 - 56)STARTEDAdalimumab 40 mg Period 2 (Weeks 56 to 260)0
Period 1 (Week 1 - 56)STARTEDUpadacitinib 15 mg Period 2 (Weeks 56 to 260)0
Period 1 (Week 1 - 56)STARTEDUpadacitinib 30 mg Period 2 (Weeks 56 to 260)0
Period 1 (Week 1 - 56)COMPLETEDPlacebo / Upadacitinib 15 mg177
Period 1 (Week 1 - 56)COMPLETEDPlacebo / Upadacitinib 30 mg178
Period 1 (Week 1 - 56)COMPLETEDAdalimumab 40 mg370
Period 1 (Week 1 - 56)COMPLETEDUpadacitinib 15 mg379
Period 1 (Week 1 - 56)COMPLETEDUpadacitinib 30 mg366
Period 1 (Week 1 - 56)COMPLETEDPlacebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)0
Period 1 (Week 1 - 56)COMPLETEDPlacebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260)0
Period 1 (Week 1 - 56)COMPLETEDAdalimumab 40 mg Period 2 (Weeks 56 to 260)0
Period 1 (Week 1 - 56)COMPLETEDUpadacitinib 15 mg Period 2 (Weeks 56 to 260)0
Period 1 (Week 1 - 56)COMPLETEDUpadacitinib 30 mg Period 2 (Weeks 56 to 260)0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03104400/flow

API referenceFor AI assistants